Selvita shows a very strong, 60% business growth in 2017

Krakow, Poland – 04 April 2018 – Selvita, one of the largest drug discovery companies in Europe, has recently published annual financial results demonstrating its strong and dynamic business performance across all segments.

Throughout 2017, Selvita Group recognized revenues from operating activities in the amount of PLN 105.9 MM – a 59% increase compared to PLN 66.7 MM in 2016.

Revenues from sales in 2017 (incl. revenues from R&D programs’ sales and excl. grants) amounted to PLN 87.8 MM, reflecting a 62% growth compared to 2016 when sales revenue amounted to PLN 54.2 MM (incl. the profit from Nodthera Ltd. share acquisition; excl. grants).

Revenues from the Services Segment in 2017 totaled PLN 44.2 MM, which represents growth of 36% in comparison to the same period of the previous year when these revenues amounted to PLN 32.4 MM.

Selvita’s Innovative Segment generated in 2017 revenues amounting to PLN 36.7 MM, reflecting 100% dynamics compared with 2016 when the revenues amounted to PLN 18.4 MM.

In 2017 Bioinformatics Segment’s revenue from sales amounted to PLN 6.9 MM, showing an increase of 101% compared to 2016, when it amounted to PLN 3.4 MM.

The value of the 2018 contracts portfolio resulting from commercial contracts and grant agreements signed as of the publication date of this report (backlog) amounts to PLN 68.7 MM. It is also worth noting that the Services Segment backlog for 2018 has increased by 48%.

The results show clearly that the company is growing strong across all divisions, enjoying continuous revenue growth. In 2017, the Services Segment of Selvita Group focused mainly on intensive growth by expanding the scope of its operations, penetrating new markets and entering into larger and long-term FTE contracts as well as integrated R&D projects. The Innovative Segment has signed one of the most important contracts in its history yet, and the Bioinformatics Segment has enjoyed another year of a fantastic business growth. In 2017, the net profit of the Selvita Group amounted to PLN 7.3 MM.

The summary of the Selvita Consolidated Annual Report for 2017 is available at: https://selvita.com/investor-relations/stock-market-reports/. The full version (in Polish) is available at: https://selvita.com/pl/centrum-inwestora/raporty-gieldowe/

 

Click to share!: